Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Off-Label Communications: Near-Term ‘Seismic Shift’ In FDA Oversight Unlikely

Jun 15 2017

• By Sue Sutter

FDA entrance sign 2016

Related Content

Unapproved Uses Bill May Eventually Pass, But Would Likely Need Additional Safeguards

Jun 08 2017

Postmarketing Studies On Abuse-Deterrent Opioids Could Get New Look

Jun 14 2017

Industry Communications With Payors: US FDA Okays Info On Investigational Drugs

Jan 19 2017

US FDA Clarifies ‘Intended Use’ Policy For Approved Products

Jan 17 2017

Off-Label Communication: When Does It Align With Approved Labeling?

Jan 18 2017

Off-Label Discussion, But No Additions, For House User Fee Bill

May 19 2017

Gottlieb Q&A: Off-Label Communications And Right-To-Try

May 03 2017

First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates

Jan 22 2017

Biopharma Wins Reprieve On US FDA 'Intended Use' Rule

Mar 18 2017

Related Companies

Endo, Inc.

Additional Topics

United States Advertising, Marketing & Sales Regulation Legislation BioPharmaceutical

More from Marketing & Advertising

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window